Trans Genic Inc. (2342.T) Comparison with companies in other sectors?

Trans Genic Inc. has a share price of 16.65M. You can analyze Trans Genic Inc. (2342.T) competitors across different market sectors through stock heatmaps.

What are 2342.T's NET and operating margins?

Trans Genic Inc. (2342.T) operating margin is around -0.02, and net profit margin is approximately -0.08 as of the latest reports.

In what way does 2342.T's earnings per share (EPS) trend reflect its financial momentum?

Trans Genic Inc. (2342.T) EPS is -65.52 (If EPS value is positive, then “signals consistent profit growth” if Negative then “signals consistent loss”). This metric is also critical in assessing valuation metrics like the P/E ratio for Trans Genic Inc. is -3.08, and the company’s ability to reinvest or distribute profits.

What does a high ROE mean for Trans Genic Inc.?

A high ROE suggests efficient use of shareholder equity to generate profit. It often signals strong management and profitability.

How do I know if AAPL is overvalued or undervalued?

Check valuation ratios for Trans Genic Inc. like P/E which is -3.09, P/B which is 0.71, and PEG which is 0.009. Compare them with sector averages to evaluate if the stock is priced fairly.

Trans Genic Inc.

2342.T•JPX

Healthcare

Biotechnology

¥202.00

¥-6.00(-2.88%)

Trans Genic Inc. (2342.T) Fundamental Analysis: Financial Health, Valuation, and Key Ratios

Dive into Apple Inc.’s fundamentals including valuation ratios, profitability, efficiency metrics, and financial health. Use this data to assess long-term investment quality and compare it with sector benchmarks.

EPS (TTM)

$-65.52

P/E Ratio

-3.08

ROE

-0.20%

Net Margin

-0.08%

Key Financial Metrices

Valuation Metrics

4 metrics

Market CapTotal market value of outstanding shares

$3.36B

Shares OutstandingTotal number of shares issued

$16.65M

Book Value/ShareNet worth per share

$291.61

Revenue/ShareAnnual revenue per share

$780.90

Profitability Metrics

6 metrics

EPS (TTM)Earnings per share trailing twelve months

$-65.52

Net MarginNet income as percentage of revenue

-8.37%

Operating MarginOperating income as percentage of revenue

-1.99%

ROEReturn on shareholders' equity

-20.04%

ROAReturn on total assets

-11.36%

ROCEReturn on capital employed

-4.11%

Cash Flow Metrics

3 metrics

Free Cash Flow/ShareCash generated per share after capex

Cash/ShareCash and equivalents per share

$153.45

FCF YieldFree cash flow as percentage of market cap

Dividend Metrics

2 metrics

Dividend/ShareAnnual dividend payment per share

Dividend YieldAnnual dividend as percentage of stock price

Financial Ratios Analysis data is not available for 2342.TFinancial Ratios Analysis details for 2342.T are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Sector Benchmarking data is not available for 2342.TSector Benchmarking details for 2342.T are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Understanding Fundamental Analysis for Trans Genic Inc. Investment Decisions

What is Fundamental Analysis?

Fundamental analysis is a method used to assess the intrinsic value of Trans Genic Inc.. Using financial reports, management structure, competitive position, and market environment, investors can determine whether the stock is undervalued or overvalued. This analysis helps investors like you make more informed investment decisions, taking into account Trans Genic Inc.'s unique business strengths and challenges.

Key Financial Metrics for Trans Genic Inc.

For Trans Genic Inc., essential financial indicators include EPS -65.52, PE -3.08, and ROE -0.20. These key ratios reveal insights into Trans Genic Inc.'s profitability, valuation, and operational health. Understanding these metrics enables you to compare Trans Genic Inc. with its industry peers and decide whether it presents a viable investment opportunity.

Profitability and Operational Efficiency of Trans Genic Inc.

Metrics like Net Margin -8.37% and ROA -11.36% shed light on how well Trans Genic Inc. is generating profits. A high profitability ratio often indicates strong management and a solid business model, which are essential for long-term growth. These metrics are crucial in assessing whether Trans Genic Inc. can sustain its operations and continue growing in the future.

Valuation and Market Position of Trans Genic Inc.

Using ratios such as P/B Ratio 0.71 and PEG Ratio 0.009, investors can assess whether Trans Genic Inc. is appropriately valued based on its financials and growth potential. These figures, combined with Trans Genic Inc.'s market capitalization, give insight into its competitive positioning and investor expectations, helping you make informed decisions on pricing and value.

Financial Health and Risk Assessment for Trans Genic Inc.

Financial health indicators, such as Debt/Equity Ratio 0.54 and Cash Flow -, provide a snapshot of Trans Genic Inc.'s ability to meet financial obligations and handle economic setbacks. A company with a strong balance sheet and solid cash flow, like Trans Genic Inc., is more likely to weather financial storms, making it a safer investment.

Long-Term Investment Strategy for Trans Genic Inc.

Investing in Trans Genic Inc. based on fundamental analysis emphasizes long-term business growth rather than short-term market trends. Investors looking at Trans Genic Inc. focus on its solid financial performance, industry standing, and competitive advantages, all of which suggest sustainable growth and the potential for steady returns over time.

Fundamental Analysis FAQ

;